Member login | Not a member? Sign up
Surgical Innovations' core business is developing instruments for keyhole or minimally invasive surgery. It has been involved in the sector since 1992 and it reversed into Aim-quoted Haemocell in 1998. The Haemocell part of the group is involved in autologous blood transfusion, which is the practice of collecting a patient's blood and re-infusing it into the body. This cuts out the risk of infection from donated blood.
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds